GSK Aims To Launch 13 Blockbusters In Five Years
Immuno-Oncology Central To Ambitions
Executive Summary
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.
You may also be interested in...
Crucial Information Coming On GSK's Investor Day Includes Consumer Health Spin-Out Details
Key investors have pledged more patience in CEO Walmsley’s turnaround but they will be expecting a convincing vision of the future, more dynamic, GSK.
Six Questions For GSK Ahead Of Crucial Investor Day
Key investors have pledged more patience in CEO Walmsley’s turnaround but they will be expecting a convincing vision of the future, more dynamic, GSK.
Cipla CEO On Lung Leadership Beyond Asthma, AMR Plans
CEO Umang Vohra outlines where Cipla is heading in its priority areas of lung route therapies and antimicrobial resistance. He also weighs in on the simmering issue of intellectual property waivers for COVID-19 vaccines.